Table 3.
Histologic diagnosis, degree of disease chronicity, and treatments received, according to development of kidney failure at last follow-up
| Characteristic | Total (N = 111) | Kidney failure (n = 29) | No kidney failure (n = 82) | P value |
|---|---|---|---|---|
| Kidney disease diagnosis | 0.47 | |||
| IgA nephropathy | 24 (22) | 5 (17) | 19 (23) | |
| Chronic interstitial nephritis | 21 (19) | 8 (28) | 13 (16) | |
| Acute interstitial nephritis | 14 (13) | 2 (7) | 12 (15) | |
| Acute tubular necrosis | 4 (4) | 0 (0) | 4 (5) | |
| Arteriosclerosis without specific changes | 6 (5) | 3 (10) | 3 (4) | |
| Secondary FSGS | 4 (4) | 1 (3) | 3 (4) | |
| Diabetic nephropathy | 3 (3) | 2 (7) | 1 (1) | |
| IC-MPGN | 6 (5) | 2 (7) | 4 (5) | |
| Severe glomerulosclerosis | 3 (3) | 2 (7) | 1 (1) | |
| AA amyloidosis | 4 (4) | 1 (3) | 3 (4) | |
| ANCA associated vasculitis | 2 (2) | 0 (0) | 2 (2) | |
| IgA vasculitis | 5 (5) | 0 (0) | 5 (6) | |
| Minimal change disease | 2 (2) | 0 (0) | 2 (2) | |
| Membranous nephropathy | 6 (5) | 3 (10) | 3 (4) | |
| C3 glomerulopathy | 1 (1) | 0 (0) | 1 (1) | |
| Thrombotic microangiopathy | 1 (1) | 0 (0) | 1 (1) | |
| Fibrillary glomerulonephritis | 1 (1) | 0 (0) | 1 (1) | |
| Lupus nephritis | 1 (1) | 0 (0) | 1 (1) | |
| Thin basement membrane | 2 (2) | 0 (0) | 2 (2) | |
| Light-chain proximal tubulopathy | 1 (1) | 0 (0) | 1 (1) | |
| Disease chronicity in kidney biopsy | ||||
| Glomerulosclerosis | 1 (0–2) | 2 (2–3) | 1 (0–2) | <0.001 |
| Interstitial fibrosis | 1 (0–2) | 2 (2–3) | 1 (0–2) | <0.001 |
| Tubular atrophy | 1 (0–2) | 2 (2–3) | 1 (0–2) | <0.001 |
| Arteriosclerosis | 1 (0–1) | 1 | 1 (0–1) | 0.001 |
| Total chronicity score | 3 (2–3) | 4 (3–5) | 2 (1–3) | <0.001 |
| Total chronicity score, N (%) | <0.001 | |||
| Minimal (0–1) | 27 (24) | 0 (0) | 27 (33) | |
| Mild (2–4) | 24 (22) | 0 (0) | 24 (29) | |
| Moderate (5–7) | 39 (35) | 13 (45) | 26 (32) | |
| Severe (≥8) | 21 (19) | 16 (55) | 5 (6) | |
| Immunosuppressive treatments received after kidney disease diagnosis | 0.65 | |||
| None | 59 (53) | 18 (62) | 41 (50) | |
| Corticosteroids | 30 (27) | 7 (24) | 23 (28) | |
| Corticosteroids + MMF | 10 (9) | 2 (7) | 8 (10) | |
| Corticosteroids + CNI | 4 (4) | 1 (3) | 3 (4) | |
| Rituximab | 4 (4) | 1 (3) | 3 (4) | |
| Other | 4 (4) | 0 (0) | 4 (5) | |
| Follow-up, months | 59 (12–109) | 13 (4–38) | 87 (23–127) | <0.001 |
AA, amyloid A; ANCA, antineutrophil cytoplasmic antibodies; CNI, calcineurin inhibitor; FSGS, focal segmental glomerulosclerosis; IC-MPGN, immune-complex membranoproliferative glomerulonephritis; IgA, immunoglobulin A; MMF, mycophenolate mofetil.